Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis

被引：0

作者：

Guttman-Yassky, Emma ^{[1
]}

Weidinger, Stephan ^{[2
]}

Simpson, Eric ^{[3
]}

Gooderham, Melinda ^{[4
,5
]}

Irvine, Alan ^{[6
]}

Spelman, Lynda ^{[7
,8
]}

Silverberg, Jonathan ^{[9
]}

Elmaraghy, Hany ^{[10
]}

DeLuca-Carter, Louise ^{[10
]}

Piruzeli, Maria Lucia Buziqui ^{[10
]}

Hu, Chaoran ^{[10
]}

Yang, Fan Emily ^{[10
]}

Pierce, Evangeline ^{[10
]}

Bardolet, Laia ^{[11
]}

Thaci, Diamant ^{[12
]}

机构：

[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[2] Univ Hosp Schleswig Holstein, Kiel, Germany

[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[4] Prob Med Res, SKiN Dermatol, Peterborough, ON, Canada

[5] Queens Univ, Peterborough, ON, Canada

[6] Childrens Hlth Ireland, Dublin, Ireland

[7] Verac Clin Res, Woolloongabba, Qld, Australia

[8] Prob Med Res, Woolloongabba, Qld, Australia

[9] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA

[10] Eli Lilly & Co, Indianapolis, IN 46285 USA

[11] Almirall SA, Barcelona, Spain

[12] Univ Lubeck, Inst & Comprehens Ctr Inflammatory Med, Lubeck, Germany

来源：

关键词：

atopic dermatitis; efficacy; lebrikizumab; phase; 3; trials; safety;

D O I：

10.1093/bjd/ljad498.005

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

494

引用

页码：II3 / II4

页数：2